Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What is the future of patient-reported outcomes in sickle-cell disease?
Singh SA, Bakshi N, Mahajan P, Morris CR. Singh SA, et al. Among authors: morris cr. Expert Rev Hematol. 2020 Nov;13(11):1165-1173. doi: 10.1080/17474086.2020.1830370. Epub 2020 Oct 15. Expert Rev Hematol. 2020. PMID: 33034214 Free PMC article. Review.
Asthma management in sickle cell disease.
Gomez E, Morris CR. Gomez E, et al. Among authors: morris cr. Biomed Res Int. 2013;2013:604140. doi: 10.1155/2013/604140. Epub 2013 Nov 10. Biomed Res Int. 2013. PMID: 24324967 Free PMC article. Review.
Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain.
Carden MA, Brousseau DC, Ahmad FA, Bennett J, Bhatt S, Bogie A, Brown K, Casper TC, Chapman LL, Chumpitazi CE, Cohen D, Dampier C, Ellison AM, Grasemann H, Hickey RW, Hsu LL, Leibovich S, Powell E, Richards R, Sarnaik S, Weiner DL, Morris CR; Sickle Cell Disease Arginine Study Group and the Pediatric Emergency Care Applied Research Network (PECARN). Carden MA, et al. Among authors: morris cr. Am J Hematol. 2019 Jun;94(6):689-696. doi: 10.1002/ajh.25471. Epub 2019 Apr 29. Am J Hematol. 2019. PMID: 30916794 Free PMC article.
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.
Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S. Farrell AT, et al. Among authors: morris cr. Blood Adv. 2019 Dec 10;3(23):4002-4020. doi: 10.1182/bloodadvances.2019000883. Blood Adv. 2019. PMID: 31809537 Free PMC article.
305 results